Bringing Scientific Precision and Patient Needs Together in ALS Research
What You Missed from ALS Industry Experts:
Mechanistic Innovation: Uncover novel insights into STMN2, UNC13A, mitochondrial dysfunction, and neuroinflammation as therapeutic targets to address ALS pathophysiology
Precision Biomarkers: Investigate advancements in TDP-43 PET tracers, NFL, and neuro-metabolic biomarkers for earlier detection and better patient stratification
Patient-Centric Clinical Design: Evaluate adaptive and decentralized trial strategies that prioritize inclusivity, reduce patient burden, and enhance regulatory alignment
Collaborative Impact: Explore how consortia like Target ALS, Answer ALS, and AMP ALS are uniting stakeholders to harmonize data and drive progress in therapy development
Who Could You Have Met?
The 4th ALS Drug Development Summit meeting united 150+ key pharma and biotech leaders across translational medicine, clinical development, biomarker and target discovery, precision, medical affairs and regulatory affairs, alongside academics, clinicians, patients, caregivers and advocates to drive more meaningful research in ALS Drug Development.
From C-Level executives to clinical research scientists, leading figures in industry met in May to discover the latest unpublished data, hear heated panel discussions, and deep-dive workshops you couldn't have found anywhere else.
What Your Peers Had to Say
